LONDON - Astex Technology Ltd. agreed to a multi-target drug discovery deal with Boehringer Ingelheim International GmbH, in which each target could yield up to $45 million in research and development costs and milestones for Astex, up to the point of commercialization. (BioWorld International) Read More
